Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea

Byung Gil Moon, Joo Yong Lee, Hyeong Gon Yu, Ji Hun Song, Young Hoon Park, Hyun Woong Kim, Yong Sok Ji, Woohyok Chang, Joo Eun Lee, Jae Ryung Oh, Inyoung Chung

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose. To evaluate the real-world efficacy and safety of the dexamethasone implant (DEX implant) in patients with diabetic macular edema (DME). Methods. Retrospective, multicenter, and noncomparative study of DME patients who were treated with at least one DEX implant. A total of 186 eyes from 165 patients were included. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), complications, and number of retreatments were collected. Data at baseline and monthly for 6 months were analyzed. Results. The average baseline BCVA and CRT were 0.60 LogMAR and 491.6 μm, respectively. The mean BCVA improved until 3 months and then decreased up to 6 months of follow-up (0.53, 0.49, and 0.55 LogMAR at 1, 3, and 6 months; p=0.001, <0.001, and 0.044, resp.). The change of mean CRT was similar to BCVA (345.0, 357.7, and 412.5 μm at 1, 3, and 6 months, p<0.001, <0.001, and <0.001, resp.). 91 eyes (48.9%) received additional treatment with anti-VEGF or DEX implant. The average treatment-free interval was 4.4 months. In group analyses, the DEX implant was more effective in pseudophakic eyes, DME with subretinal fluid (SRF), or diffuse type. Conclusions. Intravitreal dexamethasone implants are an effective treatment for patients with DME, most notably in pseudophakic eyes, DME with SRF, or diffuse type. A half of these patients require additional treatment within 6 months.

Original languageEnglish
Article number9810270
JournalJournal of Ophthalmology
Volume2016
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Macular Edema
Korea
Dexamethasone
Visual Acuity
Safety
Subretinal Fluid
Retreatment
Therapeutics
Vascular Endothelial Growth Factor A
Multicenter Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Moon, B. G., Lee, J. Y., Yu, H. G., Song, J. H., Park, Y. H., Kim, H. W., ... Chung, I. (2016). Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea. Journal of Ophthalmology, 2016, [9810270]. https://doi.org/10.1155/2016/9810270

Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea. / Moon, Byung Gil; Lee, Joo Yong; Yu, Hyeong Gon; Song, Ji Hun; Park, Young Hoon; Kim, Hyun Woong; Ji, Yong Sok; Chang, Woohyok; Lee, Joo Eun; Oh, Jae Ryung; Chung, Inyoung.

In: Journal of Ophthalmology, Vol. 2016, 9810270, 01.01.2016.

Research output: Contribution to journalArticle

Moon, BG, Lee, JY, Yu, HG, Song, JH, Park, YH, Kim, HW, Ji, YS, Chang, W, Lee, JE, Oh, JR & Chung, I 2016, 'Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea', Journal of Ophthalmology, vol. 2016, 9810270. https://doi.org/10.1155/2016/9810270
Moon, Byung Gil ; Lee, Joo Yong ; Yu, Hyeong Gon ; Song, Ji Hun ; Park, Young Hoon ; Kim, Hyun Woong ; Ji, Yong Sok ; Chang, Woohyok ; Lee, Joo Eun ; Oh, Jae Ryung ; Chung, Inyoung. / Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea. In: Journal of Ophthalmology. 2016 ; Vol. 2016.
@article{2013af0afb4d4c5da8f66947e7396e0f,
title = "Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea",
abstract = "Purpose. To evaluate the real-world efficacy and safety of the dexamethasone implant (DEX implant) in patients with diabetic macular edema (DME). Methods. Retrospective, multicenter, and noncomparative study of DME patients who were treated with at least one DEX implant. A total of 186 eyes from 165 patients were included. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), complications, and number of retreatments were collected. Data at baseline and monthly for 6 months were analyzed. Results. The average baseline BCVA and CRT were 0.60 LogMAR and 491.6 μm, respectively. The mean BCVA improved until 3 months and then decreased up to 6 months of follow-up (0.53, 0.49, and 0.55 LogMAR at 1, 3, and 6 months; p=0.001, <0.001, and 0.044, resp.). The change of mean CRT was similar to BCVA (345.0, 357.7, and 412.5 μm at 1, 3, and 6 months, p<0.001, <0.001, and <0.001, resp.). 91 eyes (48.9{\%}) received additional treatment with anti-VEGF or DEX implant. The average treatment-free interval was 4.4 months. In group analyses, the DEX implant was more effective in pseudophakic eyes, DME with subretinal fluid (SRF), or diffuse type. Conclusions. Intravitreal dexamethasone implants are an effective treatment for patients with DME, most notably in pseudophakic eyes, DME with SRF, or diffuse type. A half of these patients require additional treatment within 6 months.",
author = "Moon, {Byung Gil} and Lee, {Joo Yong} and Yu, {Hyeong Gon} and Song, {Ji Hun} and Park, {Young Hoon} and Kim, {Hyun Woong} and Ji, {Yong Sok} and Woohyok Chang and Lee, {Joo Eun} and Oh, {Jae Ryung} and Inyoung Chung",
year = "2016",
month = "1",
day = "1",
doi = "10.1155/2016/9810270",
language = "English",
volume = "2016",
journal = "Journal of Ophthalmology",
issn = "2090-004X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea

AU - Moon, Byung Gil

AU - Lee, Joo Yong

AU - Yu, Hyeong Gon

AU - Song, Ji Hun

AU - Park, Young Hoon

AU - Kim, Hyun Woong

AU - Ji, Yong Sok

AU - Chang, Woohyok

AU - Lee, Joo Eun

AU - Oh, Jae Ryung

AU - Chung, Inyoung

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose. To evaluate the real-world efficacy and safety of the dexamethasone implant (DEX implant) in patients with diabetic macular edema (DME). Methods. Retrospective, multicenter, and noncomparative study of DME patients who were treated with at least one DEX implant. A total of 186 eyes from 165 patients were included. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), complications, and number of retreatments were collected. Data at baseline and monthly for 6 months were analyzed. Results. The average baseline BCVA and CRT were 0.60 LogMAR and 491.6 μm, respectively. The mean BCVA improved until 3 months and then decreased up to 6 months of follow-up (0.53, 0.49, and 0.55 LogMAR at 1, 3, and 6 months; p=0.001, <0.001, and 0.044, resp.). The change of mean CRT was similar to BCVA (345.0, 357.7, and 412.5 μm at 1, 3, and 6 months, p<0.001, <0.001, and <0.001, resp.). 91 eyes (48.9%) received additional treatment with anti-VEGF or DEX implant. The average treatment-free interval was 4.4 months. In group analyses, the DEX implant was more effective in pseudophakic eyes, DME with subretinal fluid (SRF), or diffuse type. Conclusions. Intravitreal dexamethasone implants are an effective treatment for patients with DME, most notably in pseudophakic eyes, DME with SRF, or diffuse type. A half of these patients require additional treatment within 6 months.

AB - Purpose. To evaluate the real-world efficacy and safety of the dexamethasone implant (DEX implant) in patients with diabetic macular edema (DME). Methods. Retrospective, multicenter, and noncomparative study of DME patients who were treated with at least one DEX implant. A total of 186 eyes from 165 patients were included. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), complications, and number of retreatments were collected. Data at baseline and monthly for 6 months were analyzed. Results. The average baseline BCVA and CRT were 0.60 LogMAR and 491.6 μm, respectively. The mean BCVA improved until 3 months and then decreased up to 6 months of follow-up (0.53, 0.49, and 0.55 LogMAR at 1, 3, and 6 months; p=0.001, <0.001, and 0.044, resp.). The change of mean CRT was similar to BCVA (345.0, 357.7, and 412.5 μm at 1, 3, and 6 months, p<0.001, <0.001, and <0.001, resp.). 91 eyes (48.9%) received additional treatment with anti-VEGF or DEX implant. The average treatment-free interval was 4.4 months. In group analyses, the DEX implant was more effective in pseudophakic eyes, DME with subretinal fluid (SRF), or diffuse type. Conclusions. Intravitreal dexamethasone implants are an effective treatment for patients with DME, most notably in pseudophakic eyes, DME with SRF, or diffuse type. A half of these patients require additional treatment within 6 months.

UR - http://www.scopus.com/inward/record.url?scp=84973376966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973376966&partnerID=8YFLogxK

U2 - 10.1155/2016/9810270

DO - 10.1155/2016/9810270

M3 - Article

AN - SCOPUS:84973376966

VL - 2016

JO - Journal of Ophthalmology

JF - Journal of Ophthalmology

SN - 2090-004X

M1 - 9810270

ER -